Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib Plus Lorigerlimab in pMMR/MSS Localized Rectal Cancer
NCT07223567Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules, Bispecific Antibodies, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of lorigerlimab, regorafenib in rectal cancer, sponsored by University of Texas MD Anderson Cancer Center. Planned start Oct 2025; status: withdrawn.
02
Drugs
lorigerlimabregorafenib
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07223567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223567.